CorporateMerger or Acquisition2026-05-20🇫🇷
SERB signs deal to acquire Idefirix rights for $133.6 million
source: SERB Pharmaceuticals -> target: Hansa Biopharma
On 2026-05-20, SERB Pharmaceuticals signed an agreement to acquire exclusive development and commercialisation rights to Idefirix (imlifidase) from Hansa Biopharma. The deal is valued at €115 million ($133.6 million) and awaits customary regulatory clearances, including foreign direct investment approval.
0.20Significance3.0Magnitude0.2Systemic0.3Market1Articles
Location
FranceEuropeFranceEurope46.228, 2.214
Story Links